Table 3.
Early events stratified according to identified phenotype with complete follow-up
| Outcomes | Event at 6 months (%) | Relative Risk (95% CI) | Event at 1 year (%) | Relative Risk (95% CI) |
|---|---|---|---|---|
| Mild CTRCD | 41 / 168 (24.4) | 48 / 149 (32.2) | ||
| Cluster 0 | 15 / 55 (27.3) | Reference | 17 / 50 (34.0) | Reference |
| Cluster 1 | 2 / 21 (9.5) | 0.35 (0.09–1.40) | 2 / 16 (12.5) | 0.37 (0.10–1.42) |
| Cluster 2 | 15 / 44 (34.1) | 1.25 (0.69–2.27) | 15 / 40 (37.5) | 1.10 (0.63–1.92) |
| Cluster 3 | 9 / 48 (18.8) | 0.69 (0.33–1.43) | 14 / 43 (32.6) | 0.96 (0.54–1.71) |
| Moderate CTRCD | 11 / 168 (6.5) | 10 / 149 (6.7) | ||
| Cluster 0 | 8 / 55 (14.5) | Reference | 6 / 50 (12.0) | Reference |
| Cluster 1 | 1 / 21 (4.8) | 0.33 (0.04–2.46) | 1 / 16 (6.3) | 0.52 (0.07–4.01) |
| Cluster 2 | 1 / 44 (2.3) | 0.16 (0.02–1.20) | 1 / 40 (2.5) | 0.21 (0.03–1.66) |
| Cluster 3 | 1 / 48 (2.1) | 0.14 (0.02–1.10) | 2 / 43 (4.7) | 0.39 (0.08–1.82) |
| Hypertensive response | 18 / 168 (10.7) | 20 / 149 (13.4) | ||
| Cluster 0 | 9 / 55 (16.4) | Reference | 9 / 50 (18.0) | Reference |
| Cluster 1 | 0 / 21 (0.0) | 0.13 (0.01–2.20) | 0 / 16 (0.0) | 0.15 (0.01–2.57) |
| Cluster 2 | 7 / 44 (15.9) | 0.97 (0.39–2.40) | 9 / 40 (22.5) | 1.25 (0.55–2.85) |
| Cluster 3 | 2 / 48 (4.2) | 0.25 (0.06–1.12) | 2 / 43 (4.7) | 0.26 (0.06–1.13) |
ABBREVIATIONS CTRCD, cancer therapy-related cardiac dysfunction